Payment overview · 2025
General Payments
$14,044.75
41 reported records · 15 companies
Healthcare provider profile · identity verified
Nathan Sailor, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · TRAVERSE CITY, MI · NPI 1194017160
Verified facts
What the public records show
CMS Open Payments records show Nathan Sailor, D.O. received $14,044.75 in general payments during 2025 across 41 reported records.
Novo Nordisk Inc accounted for 92.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Symbicort by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Xarelto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $12,973.30 | 92.4% | 10 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $254.54 | 1.8% | 12 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $188.72 | 1.3% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $180.61 | 1.3% | 4 | 2025 |
| Braeburn Inc. | Unresolved — no canonical attribution shown | $137.36 | 1.0% | 2 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $94.13 | 0.7% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $35.89 | 0.3% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $29.05 | 0.2% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $26.72 | 0.2% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $23.42 | 0.2% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $23.00 | 0.2% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $21.78 | 0.2% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $19.44 | 0.1% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $19.21 | 0.1% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $17.58 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $12,228.13 | 4 |
| Food and Beverage | $1,329.24 | 34 |
| Travel and Lodging | $487.38 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $12,954.81 | 9 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $188.72 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $138.40 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $137.44 | 2 | 2025 |
Source payment records
|
|||||
| BRIXADI Normalized: brixadi |
Drug | Braeburn Inc. | $137.36 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $99.49 | 3 | 2025 |
Source payment records
|
|||||
| Vyrsa V1 Normalized: vyrsa v1 |
Device | Globus Medical, Inc. | $94.13 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $92.15 | 7 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $56.32 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $50.33 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $35.89 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $29.05 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $26.72 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $23.42 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $23.00 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $21.78 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $19.44 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $19.21 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $18.49 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $18.49 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $18.05 | 1 | 2025 |
Source payment records
|
|||||
| ESPRIT Normalized: esprit |
Device | Abbott Laboratories | $17.58 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 88 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
29 | 29 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
88 | 24 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 256 | 84 |
| Levothyroxine Sodium | Levothyroxine Sodium | 208 | 59 |
| Omeprazole | Omeprazole | 200 | 70 |
| Amlodipine Besylate | Amlodipine Besylate | 185 | 62 |
| Gabapentin | Gabapentin | 167 | 34 |
| Losartan Potassium | Losartan Potassium | 161 | 60 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 152 | 35 |
| Lisinopril | Lisinopril | 145 | 52 |
| Tramadol Hcl | Tramadol Hcl | 143 | 29 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 139 | 50 |
| Pantoprazole Sodium | Pantoprazole Sodium | 132 | 49 |
| Metoprolol Succinate | Metoprolol Succinate | 128 | 45 |
| Prednisone | Prednisone | 125 | 83 |
| Tamsulosin Hcl | Tamsulosin Hcl | 114 | 41 |
| Trulicity | Dulaglutide | 110 | 18 |
| Jardiance | Empagliflozin | 100 | 32 |
| Metformin Hcl | Metformin Hcl | 99 | 38 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 97 | 43 |
| Alprazolam | Alprazolam | 95 | 20 |
| Trazodone Hcl | Trazodone Hcl | 94 | 35 |
| Simvastatin | Simvastatin | 90 | 27 |
| Eliquis | Apixaban | 88 | 24 |
| Potassium Chloride | Potassium Chloride | 88 | 38 |
| Furosemide | Furosemide | 81 | 35 |
| Ibuprofen | Ibuprofen | 76 | 20 |
| Hydrochlorothiazide | Hydrochlorothiazide | 75 | 24 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 75 | 25 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 73 | 23 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 67 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 66 | 19 |
| Allopurinol | Allopurinol | 62 | 20 |
| Meloxicam | Meloxicam | 61 | 21 |
| Carvedilol | Carvedilol | 60 | 18 |
| Metformin Hcl Er | Metformin Hcl | 59 | 20 |
| Clonazepam | Clonazepam | 57 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 57 | 49 |
| Mounjaro | Tirzepatide | 53 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 52 | 19 |
| Azithromycin | Azithromycin | 51 | 40 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 51 | 21 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 48 | 38 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 43 | 32 |
| Cephalexin | Cephalexin | 43 | 30 |
| Spironolactone | Spironolactone | 43 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 41 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 40 | 20 |
| Metoprolol Tartrate | Metoprolol Tartrate | 39 | 13 |
| Ondansetron Odt | Ondansetron | 39 | 19 |
| Ozempic | Semaglutide | 37 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 37 | 12 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 36 | 11 |
| Lorazepam | Lorazepam | 36 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 35 | 14 |
| Sertraline Hcl | Sertraline Hcl | 34 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 34 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 33 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 33 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 33 | 12 |
| Ventolin Hfa | Albuterol Sulfate | 33 | 20 |
| Farxiga | Dapagliflozin Propanediol | 30 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 29 | 29 |
| Bupropion Xl | Bupropion Hcl | 28 | suppressed |
| Pregabalin | Pregabalin | 28 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 28 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 28 | 15 |
| Xarelto | Rivaroxaban | 27 | suppressed |
| Famotidine | Famotidine | 26 | 12 |
| Montelukast Sodium | Montelukast Sodium | 26 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 25 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 25 | suppressed |
| Methocarbamol | Methocarbamol | 24 | 11 |
| Ketoconazole | Ketoconazole | 23 | 19 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 22 | suppressed |
| Asa-Butalb-Caffeine-Codeine | Codeine/Butalbital/Asa/Caffein | 21 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 21 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 21 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 21 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 21 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 20 | suppressed |
| Mirtazapine | Mirtazapine | 20 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 19 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 18 | 18 |
| Buspirone Hcl | Buspirone Hcl | 18 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 18 | suppressed |
| Lactulose | Lactulose | 18 | suppressed |
| Lovastatin | Lovastatin | 18 | suppressed |
| Aripiprazole | Aripiprazole | 17 | suppressed |
| Diazepam | Diazepam | 17 | suppressed |
| Estradiol | Estradiol | 17 | suppressed |
| Synthroid | Levothyroxine Sodium | 17 | suppressed |
| Bumetanide | Bumetanide | 16 | suppressed |
| Chlorthalidone | Chlorthalidone | 16 | suppressed |
| Colchicine | Colchicine | 16 | suppressed |
| Finasteride | Finasteride | 16 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Rybelsus | Semaglutide | 16 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Gemtesa | Vibegron | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 14 | suppressed |
| Zonisamide | Zonisamide | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Ezetimibe | Ezetimibe | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 13 | suppressed |
| Cosentyx Sensoready (2 Pens) | Secukinumab | 12 | suppressed |
| Levofloxacin | Levofloxacin | 12 | 12 |
| Methenamine Hippurate | Methenamine Hippurate | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 12 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 12 | suppressed |
| Atenolol | Atenolol | 11 | suppressed |
| Celecoxib | Celecoxib | 11 | suppressed |
| Dutasteride | Dutasteride | 11 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $14,044.75 · 41 records | Novo Nordisk Inc | AIRSUPRA, AUSTEDO XR, Auvelity, BREZTRI, BRIXADI, CAPLYTA, Cologuard Collection Kit, ELIQUIS, ESPRIT, FARXIGA, JOURNAVX, Korlym, NURTEC ODT, Ozempic, QULIPTA, REXULTI, Rybelsus, SPRAVATO, UBRELVY, VRAYLAR, Vyrsa V1, Wegovy | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error